Jazz Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 80

Jazz Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Jazz Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011” provides data on the Jazz Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Jazz Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Jazz Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Jazz Pharmaceuticals, Inc. - Brief Jazz Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Jazz Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Jazz Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Jazz Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Jazz Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Jazz Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Jazz Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Jazz Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Jazz Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Jazz Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc. - Key Therapeutics; Jazz Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Jazz Pharmaceuticals, Inc. - News; Jazz Pharmaceuticals, Inc. - Latest Updates; Jazz Pharmaceuticals, Inc. - Pipeline; Jazz Pharmaceuticals, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Jazz Pharmaceuticals, Inc. Snapshot
Jazz Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Jazz Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Jazz Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Jazz Pharmaceuticals, Inc. – Pipeline Products Glance
Jazz Pharmaceuticals, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Jazz Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Jazz Pharmaceuticals, Inc. – Drug Profiles
JZP-4
JZP-6
JZP-7
JZP-8
Jazz Pharmaceuticals, Inc. – Pipeline Analysis
Jazz Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Jazz Pharmaceuticals, Inc. - Pipeline Products By Target
Jazz Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Jazz Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Jazz Pharmaceuticals, Inc. – Recent Pipeline Updates
Jazz Pharmaceuticals, Inc. - Dormant Projects
Jazz Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
JZP-2
Jazz Pharmaceuticals, Inc. – Company Statement
Jazz Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jun 24, 2010: Jazz Announces That The FDA's Arthritis Advisory Committee And Drug Safety And Risk Management Advisory Committee Will review JZP-6 (sodium oxybate)
Aug 20, 2010: Jazz Pharmaceuticals Provides Update on FDA Advisory Committee Meeting For JZP-6 (Sodium Oxybate) in Fibromyalgia
Aug 20, 2010: Jazz Pharmaceuticals Provides Update On FDA Advisory Committee Meeting For JZP-6 In Fibromyalgia
Feb 18, 2010: Jazz Pharmaceuticals Announces FDA Acceptance of its New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
Feb 18, 2010: Jazz Pharmaceuticals Announces FDA Acceptance Of NDA For JZP-6 For Treatment Of Fibromyalgia
Feb 16, 2010: Abbott Completes Acquisition of Solvay Pharmaceuticals
Oct 11, 2011: Jazz Receives FDA Complete Response Letter Regarding JZP-6 For Treatment Of Fibromyalgia
Oct 11, 2010: Jazz Receives FDA Complete Response Letter For JZP-6 For Treatment Of Fibromyalgia
Financial Deals Landscape
Jazz Pharmaceuticals, Inc., Deals Summary
Jazz Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Jazz Pharmaceuticals Raises $250 Million In Series B Financing
Jazz Pharmaceuticals Raises $35 Million In Series B Financing
Merger
Azur Pharma To Merge With Jazz Pharmaceuticals In All Stock Transaction
Licensing Agreements
FAES Farma Enters Into Licensing Agreement With Jazz Pharmaceuticals
Jazz Pharmaceuticals Enters Into Sub-Licensing Agreement With Anchen
Antares Pharma Enters Into Licensing Agreement With Jazz Pharmaceuticals
Jazz Pharmaceuticals Enters Into Licensing Agreement With Solvay
Valeant Pharmaceuticals Enters into Licensing Agreement With Jazz Pharmaceuticals
UCB Pharma Expands Licensing Agreement With Jazz Pharmaceuticals
Accelrys Enters Into Licensing Agreement With Jazz Pharmaceuticals
Jazz Pharmaceuticals Enters Into Agreement With GlaxoSmithKline
Equity Offering
Jazz Pharmaceuticals Completes Public Offering Of $58.45 Million
Jazz Pharmaceuticals Completes Private Placement Of $120 Million
Jazz Pharmaceuticals Completes Private Placement Of $7 Million
Jazz Pharmaceuticals Completes Private Placement Of $26 Million
Jazz Pharmaceuticals Amends Private Placement To Raise $75 Million
Jazz Completes Initial Public Offering Of $108 Million
Debt Offering
Jazz Completes Private Placement Of $40 Million
Orphan Medical Completes Private Placement Of Senior Secured Notes For $80 Million
Jazz Pharmaceuticals Issues Senior Secured Notes For $80 Million
Asset Transactions
Paladin Labs Acquires Antizol, Antizol-Vet And Related Assets From Jazz Pharmaceuticals
Orphan Europe Acquires Cystadane And Related Product Rights From Jazz Pharmaceuticals
Acquisition
Jazz Pharmaceuticals Acquires Orphan Medical
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Jazz Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Jazz Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Jazz Pharmaceuticals, Inc. – Filed, H2 2011
Jazz Pharmaceuticals, Inc. - Phase II, H2 2011
Jazz Pharmaceuticals, Inc. - Phase I, H2 2011
Jazz Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011
Jazz Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Jazz Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Jazz Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011
Jazz Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011
Jazz Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010
Jazz Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2010
Jazz Pharmaceuticals, Inc., Subsidiaries
Jazz Pharmaceuticals, Inc., Deals Summary
Jazz Pharmaceuticals Raises $250 Million In Series B Financing
Jazz Pharmaceuticals Raises $35 Million In Series B Financing
Azur Pharma To Merge With Jazz Pharmaceuticals In All Stock Transaction
FAES Farma Enters Into Licensing Agreement With Jazz Pharmaceuticals
Jazz Pharmaceuticals Enters Into Sub-Licensing Agreement With Anchen
Antares Pharma Enters Into Licensing Agreement With Jazz Pharmaceuticals
Jazz Pharmaceuticals Enters Into Licensing Agreement With Solvay
Valeant Pharmaceuticals Enters into Licensing Agreement With Jazz Pharmaceuticals
UCB Pharma Expands Licensing Agreement With Jazz Pharmaceuticals
Accelrys Enters Into Licensing Agreement With Jazz Pharmaceuticals
Jazz Pharmaceuticals Enters Into Agreement With GlaxoSmithKline
Jazz Pharmaceuticals Completes Public Offering Of $58.45 Million
Jazz Pharmaceuticals Completes Private Placement Of $120 Million
Jazz Pharmaceuticals Completes Private Placement Of $7 Million
Jazz Pharmaceuticals Completes Private Placement Of $26 Million
Jazz Pharmaceuticals Amends Private Placement To Raise $75 Million
Jazz Completes Initial Public Offering Of $108 Million
Jazz Completes Private Placement Of $40 Million
Orphan Medical Completes Private Placement Of Senior Secured Notes For $80 Million
Jazz Pharmaceuticals Issues Senior Secured Notes For $80 Million
Paladin Labs Acquires Antizol, Antizol-Vet And Related Assets From Jazz Pharmaceuticals
Orphan Europe Acquires Cystadane And Related Product Rights From Jazz Pharmaceuticals
Jazz Pharmaceuticals Acquires Orphan Medical

List of Figures
Jazz Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Jazz Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Jazz Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, H2 2011
Jazz Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Jazz Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011

Customers who bought this item also bought

• IBM Rational Jazz: The Story So Far
• Idenix Pharmaceuticals, Inc.
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Analysis of Google Inc
• Scientific Games Corporation - Company Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Abbott Laboratories - IT Sales Opportunities - 2009
• Ixia - Company Analysis
• Kuehne and Nagel - IT Sales Opportunities - 2009